Sellas Life Sciences

SELLAS™ Life Sciences Receives FDA Fast Track Designation of Galinpepimut-S for the Treatment of Malignant Pleural Mesothelioma

-Follows Fast Track Designation of Galinpepimut-S for the Treatment of Acute Myeloid Leukemia (AML) ZUG, Switzerland, and NEW YORK, September 19, 2016 /PRNewswire/ — SELLAS™ Life Sciences Group (SELLAS), a development-stage biopharmaceutical company focused on developing...
Read More →

SELLAS™ Life Sciences Announces Entry Into Cooperative Research and Development Agreement With National Heart, Lung and Blood Institute, National Institutes of Health

Goal of the Collaborative Effort is to Develop an Effective Testing Method to Monitor Minimal Residual Disease (MRD) and to Develop Diagnostic Testing for Acute Myeloid Leukemia (AML)   SELLAS to Collaborate with the Myeloid Malignancies Section, Hematology Branch, NHLBI and the...
Read More →